Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice

MLA

Deniz Tural, et al. Long-Term Outcome and Safety in Patients Treated with Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience from Real-World Clinical Practice. Jan. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....26dc21e7da2e7871260bfc6595b9ec98&authtype=sso&custid=ns315887.

APA

Deniz Tural, Cagatay Arslan, Fatih Selcukbiricik, Omer Fatih Olmez, Mustafa Erman, Yüksel Ürün, Nuri Karadurmus, Emre Akar, & Saadettin Kilickap. (2022). Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.

Chicago

Deniz Tural, Cagatay Arslan, Fatih Selcukbiricik, Omer Fatih Olmez, Mustafa Erman, Yüksel Ürün, Nuri Karadurmus, Emre Akar, and Saadettin Kilickap. 2022. “Long-Term Outcome and Safety in Patients Treated with Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience from Real-World Clinical Practice,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....26dc21e7da2e7871260bfc6595b9ec98&authtype=sso&custid=ns315887.